摘要
目的：观察氨溴索在慢性阻塞性肺疾病（ＣＯＬＤ）急性发作期的疗效。方法：４８例随机分为氨溴索组２４例（男性１６例，女性８例；年龄６１±ｓ１３ａ）和对照组２４例（男性１８例，女性６例；年龄５９±１５ａ）。２组常规治疗（头孢拉定、阿米卡星、二羟丙茶碱或氨茶碱、溴己新）相同，前者加服氨溴索３０ｍｇ，ｐｏ，ｔｉｄ×２ｗｋ。结果：治疗１ｗｋ后痰量增加；１ｗｋ和２ｗｋ后咳嗽频率、咳嗽难度和痰液粘稠度减轻，氨溴索组优于对照组（Ｐ＜０．０５）；２ｗｋ后痰量明显减少，但组间无差异（Ｐ＞０．０５）。未发现副作用。结论：氨溴索有良好痰液溶解作用，可作为治疗ＣＯＬＤ的辅助药物。
AIM: To observe the effects of ambroxol in treating chronic obstructive lung diseases (COLD). METHODS: Forty-eight patients with COLD were divided at random into two groups. The ambroxol group ( M 16, F 8; age 61±s 13 a) was treated with ambroxol tablet 30 mg, po, tid for 2 wk on top of the routine therapy (cefradine, amikacin, diprophylline or aminophylline, bromhexine), and the control group (M 18, F 6; age 59±15 a) received the same routine therapy but no ambroxol. RESULTS: The quantity of sputum was increased in both groups after 1 wk treatment (more in amborxol group than in the control), decreased in both groups and without difference between the two groups after 2 wk. Ambroxol produced symptomatic improvements in frequency of cough, difficulty in expectoration and thickness of sputum as compared to control (P< 0.05) after 1 or 2 wk. Adverse effect were not seen. CONCLUSION: Ambroxol is an expectorant for the treatment of COLD.
出处
《新药与临床》
CSCD
北大核心
1997年第5期271-272,共2页
关键词
氨溴索
祛痰剂
阻塞性肺疾病
治疗
ambroxol
expectorants
obstructive lung diseases
sputum
